Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basiliximab with optimized cyclosporine in liver transplantation
NCT00343226Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2002
- Primary completion
- Apr 2005
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, open-label trial of basiliximab in Liver transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Glomerular Filtration Rate at 12 months. Started May 2002; status: completed.
02
Drugs
basiliximab
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT00343226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343226.